buyWeak cluster of 2
David Baltimore bought $21k of RGLS
director at Regulus Therapeutics Inc.. 19,610 shares at an average of $1.06, traded Jan 30, 2025, filed Jan 31, 2025.
Conviction score
33Value
$21k
19,610 shares
Holdings after
22,169
+766% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- 0Trade size$21k at market
- +10Relative to holdingsHoldings up 766%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-011850, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 30, 2025 | POpen-market purchase Common Stock | +19,610 | $1.06 | $21k | 22,169 | Jan 31, 2025 |
Related signals
Other insiders at Regulus Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | RGLSbuy Regulus Therapeutics Inc. | Preston Klassen President & Head of R & D | $96k 12,000 shares | +33% | |
| 46Moderate | Regulus Therapeutics Inc. | Joseph P Hagan Chief Executive Officer | $54k 50,000 shares | +24% | |
| 27Weak | Regulus Therapeutics Inc. | Christopher Ray Aker Sr. VP & General Counsel | $55k 43,635 shares | -47% | |
| 34Weak | Regulus Therapeutics Inc. | Crispina Calsada Chief Financial Officer | $55k 43,804 shares | -49% | |
| 41Moderate | Regulus Therapeutics Inc. | Joseph P Hagan Chief Executive Officer | $160k 127,054 shares | -38% | |
| 31Weak | Regulus Therapeutics Inc. | Preston Klassen President & Head of R & D | $40k 31,445 shares | -47% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.